The U.S. Food and Drug Administration (FDA) is continuing its transition toward more structured electronic submissions for medical device premarket review. In September 2026, FDA issued a new Draft Guidance titled “Electronic Submission Template for Premarket Approval Applications (PMA).” The guidance introduces the agency’s developing framework for electronic submission templates for Premarket Approval applications and certain PMA supplements. While the guidance is currently